Information Provided By:
Fly News Breaks for February 14, 2020
BTAI
Feb 14, 2020 | 07:48 EDT
SunTrust analyst Robyn Karnauskas raised her price target on BioXcel Therapeutics to $150 after updating her model with added sales for opioid withdrawal as well as dementia/schizo/bipolar treatments. The analyst contends that with two pivotal trials and two Phase 2s trials taking place this year, investors are "missing how quickly these data sets will come and also how quickly the company can complete additional Phase 3 trials". Karnauskas is keeping her Buy rating on BioXcel Therapeutics given its expected catalyst-rich 2020.
News For BTAI From the Last 2 Days
BTAI
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.